# A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

> **NCT06782373** · PHASE2 · RECRUITING · sponsor: **Swedish Orphan Biovitrum** · enrollment: 78 (estimated)

## Conditions studied

- VEXAS
- VEXAS Syndrome

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06782373
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-28
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-05-22
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06782373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06782373, "A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06782373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*